On February 14, Cansino Biologics Inc(688185) (688185, SH) announced that it had received the short form report on changes in equity from shareholders. Shanghai Li'an, Suzhou li'tai, LAV spring, LAV bio, Lilly Asia and LAV amber reduced Cansino Biologics Inc(688185) A shares and H shares by about 7.94 million from September 6, 2021 to February 11, 2022.
The reporter of the daily economic news noted that the shareholders of the above Cansino Biologics Inc(688185) are the investors of Lilly Asia ventures, which are managed by the Lilly Asia Fund team and act in concert.
In fact, the investors of Lilly Asia Fund have been lurking in Cansino Biologics Inc(688185) investment for nearly 10 years. At the end of January this year, Cansino Biologics Inc(688185) is expected to have a net profit of 1.85 billion yuan to 2 billion yuan in 2021.
The reduction of Cansino Biologics Inc(688185) by the relevant investors of Lilly Asia fund began in the A-share market and H-share market respectively. The investors in the A-share market announced the reduction plan after the lifting of the ban last year. Up to now, they have reduced their holdings of about 4.79 million shares; The investors in the Hong Kong stock market of the fund reduced Cansino Biologics Inc(688185) about 3.15 million shares on January 11.
latent investment Cansino Biologics Inc(688185) recent 10 years
Lav spring's stake in Cansino Biologics Inc(688185) dates back to August 2013. At that time, when Cansino Biologics Inc(688185) conducted the second round of financing, LAV spring's investment in Cansino Biologics Inc(688185) was about US $60.5 million. Subsequently, Shanghai Li'an invested about 23 million yuan in Cansino Biologics Inc(688185) in the third round of financing.
In September 2015, Suzhou Litai, Lilly Asia and LAV bio invested 15.52 million yuan, 15.52 million yuan and 31.05 million yuan respectively in Cansino Biologics Inc(688185) .
In 2017, Cansino Biologics Inc(688185) issued new shares. Lilly Asia subscribed for 21.7 million yuan, Suzhou Litai subscribed for 21.7 million yuan and LAV bio subscribed for 43.4 million yuan. Before Cansino Biologics Inc(688185) was listed in Hong Kong, the relevant investment entities of Lilly Asia fund controlled about 18.75% of the shares of Cansino Biologics Inc(688185) .
By April 2020, before the listing of Cansino Biologics Inc(688185) A shares, LAV spring held about 4.67%, LAV bio held about 2.21%, Shanghai Li'an held about 2.07%, Suzhou Li Tai held about 1.4% and Lilly Asia held about 1.1%. According to Cansino Biologics Inc(688185) announcement, among the investment entities of these Lilly Asia funds, only the shares held by Shanghai Li'an and Suzhou Li Tai belong to a shares, and the shares held by other investment entities are H shares.
the share price has fallen nearly 70% from its peak
The reduction plan of Cansino Biologics Inc(688185) A shares by the investors under the name of Lilly Asia Fund was announced in August last year. Before the reduction, Shanghai Li'an and Suzhou li'tai jointly held Cansino Biologics Inc(688185) about 7.71 million shares, accounting for about 3.12% of the total shares of the company. These shares of Shanghai Li'an and Suzhou li'tai were listed and circulated from August 13, 2021.
According to the reduction plan of Shanghai Li'an and Suzhou li'tai at that time, the reduction period of competitive trading is from September 6, 2021 to March 5, 2022, and the upper limit of reduction is 100% of the shares held by the two companies.
According to the previous announcement of Cansino Biologics Inc(688185) , as of January 10, 2022, Shanghai Li'an and Suzhou Li Tai have reduced their holdings of about 4.58 million shares in this reduction plan, accounting for about 1.85% of the total shares of the company, and more than half of them have been reduced. The price range of the reduction of the two companies is 273.46 yuan / share - 311.37 yuan / share, and the amount of reduction is about 780 million yuan and 520 million yuan respectively.
The reporter of the daily economic news noted that although Lilly Asia Fund's reduction of Cansino Biologics Inc(688185) can be said to benefit a lot compared with its investment, its reduction price is not high compared with the peak of Cansino Biologics Inc(688185) share price. On June 23 last year, Cansino Biologics Inc(688185) set a high price of 798 yuan / share, but the ban on Cansino Biologics Inc(688185) shares held by Shanghai Li'an and Suzhou Li Tai was not lifted at that time.
Subsequently, the share price of Cansino Biologics Inc(688185) began to decline all the way. By February 14 this year, the daily closed at 252.98 yuan / share, which has fallen nearly 70% compared with the high point in June last year.
According to the announcement of the Cansino Biologics Inc(688185) "change in shareholders' equity of more than 5%, the reduction of shares of Shanghai Li'an and Suzhou Li Tai is still ongoing. By February 11, the total reduction of shares of the two companies has reached 4.79 million shares. The relevant investors of Lilly Asia Fund in H shares reduced Cansino Biologics Inc(688185) about 3.15 million shares on January 11.
According to Cansino Biologics Inc(688185) announcement, after the equity change, the shareholding ratio of relevant investors of Lilly Asia Fund in Cansino Biologics Inc(688185) decreased to 4.99%.
On January 29, Cansino Biologics Inc(688185) released the annual performance forecast for 2021, which is expected to achieve an operating revenue of about 4.2 billion yuan to 4.4 billion yuan in 2021, with a year-on-year increase of 16773.97% to 17577.49%; The net profit attributable to the owners of the parent company was 1.85 billion yuan to 2 billion yuan, turning losses into profits compared with the previous year.
For the growth of the 2021 annual performance, Cansino Biologics Inc(688185) said that during the reporting period, the New Coronavirus vaccine (5 adenovirus vector) (the trade name: Ke Wei Sha) had been granted China's conditional approval and emergency use authorization in many other countries, which had a positive impact on the company's main business income and net profit attributable to the owner's owner.
full name abbreviation comparison
Shanghai Li'an venture capital center (limited partnership) (hereinafter referred to as "Shanghai Li'an")
Suzhou Litai venture capital center (limited partnership) (hereinafter referred to as "Suzhou Litai")
\u3000\u3000LAV Spring(Hong Kong)Co。， Limited ("LAV spring")
\u3000\u3000LAV BioIII Investment(Hong Kong)Co。， Limited ("LAV bio")
\u3000\u3000Lilly Asia VenturesIII Investment(Hong Kong)Co。， Limited ("Lilly Asia")
Lav amber Limited ("LAV amber")
